Evidence map›Paper›PMID 30188899›Full record

Trial reportPloS one2018

Spinal muscular atrophy within Amish and Mennonite populations: Ancestral haplotypes and natural history.

Vincent J Carson, Erik G Puffenberger, Lauren E Bowser, Karlla W Brigatti, Millie Young, Dominika Korulczyk, Ashlin S Rodrigues, KaLynn K Loeven, Kevin A Strauss

Open access · goldAbstract readClinical Trial
In one paragraph

Trial report in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 3 pooled it
0.1field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 3 syntheses or guidelines pooled it, 12 citations in OpenAlex.

  1. Pooled it
  2. The impact of threeFrontiers in neurology · 2024
    Pooled it
  3. Pooled it
  4. Article
  5. Exonic Variation and Its Clinical Impact in 7221 Old Order Amish.American journal of medical genetics. Part A · 2025
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Vincent J CarsonClinic for Special Children, Strasburg, Pennsylvania, United States of America.
Erik G PuffenbergerClinic for Special Children, Strasburg, Pennsylvania, United States of America.ORCID 0000-0002-6388-9148
Lauren E BowserClinic for Special Children, Strasburg, Pennsylvania, United States of America.
Karlla W BrigattiClinic for Special Children, Strasburg, Pennsylvania, United States of America.ORCID 0000-0002-9178-815X
Millie YoungClinic for Special Children, Strasburg, Pennsylvania, United States of America.ORCID 0000-0001-6014-5189
Dominika KorulczykClinic for Special Children, Strasburg, Pennsylvania, United States of America.ORCID 0000-0002-0226-8305
Ashlin S RodriguesClinic for Special Children, Strasburg, Pennsylvania, United States of America.
KaLynn K LoevenClinic for Special Children, Strasburg, Pennsylvania, United States of America.
Kevin A StraussClinic for Special Children, Strasburg, Pennsylvania, United States of America.ORCID 0000-0002-6429-8657
Clinic for Special Children · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We correlate chromosome 5 haplotypes and SMN2 copy number with disease expression in 42 Mennonite and 14 Amish patients with spinal muscular atrophy (SMA). A single haplotype (A1) with 1 copy of SMN2 segregated among all Amish patients. SMN1 deletions segregated on four different Mennonite haplotypes that carried 1 (M1a, M1b, M1c) or 2 (M2) copies of SMN2. DNA microsatellite and microarray data revealed structural similarities among A1, M1a, M1b, and M2. Clinical data were parsed according to both SMN1 genotype and SMN2 copy number (2 copies, n = 44; 3 copies, n = 9; or 4 copies, n = 3). No infant with 2 copies of SMN2 sat unassisted. In contrast, all 9 Mennonites with the M1a/M2 genotype (3 copies of SMN2) sat during infancy at a median age of 7 months, and 5 (56%) walked and dressed independently at median ages of 18 and 36 months, respectively. All are alive at a median age of 11 (range 2-31) years without ventilatory support. Among 13 Amish and 26 Mennonite patients with 2 copies of SMN2 who did not receive feeding or ventilatory support, A1/A1 as compared to M1a/M1a genotype was associated with earlier clinical onset (p = 0.0040) and shorter lifespan (median survival 3.9 versus 5.7 months, p = 0.0314). These phenotypic differences were not explained by variation in SMN1 deletion size or SMN2 coding sequence, which were conserved across haplotypes. Distinctive features of SMA within Plain communities provide a population-specific framework to study variations of disease expression and the impact of disease-modifying therapies administered early in life.

Indexed as

Gene DosageAmishChild, PreschoolChromosomes, Human, Pair 5FemaleHumansInfantInfant, NewbornMaleMuscular Atrophy, SpinalSurvival of Motor Neuron 1 ProteinSurvival of Motor Neuron 2 ProteinSMN1 protein, humanSMN2 protein, humanSurvival of Motor Neuron 1 ProteinSurvival of Motor Neuron 2 Protein

Identifiers

PMID30188899
PMCPMC6126807
OpenAlexW2890540796

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.